fda tirzepatide injection shortage resolved october 2 2024 Says Compounded Must Exit the Market Tirzepatide Shortage Resolved? FDA Says

What does not exist, at least as of the current published literature, is a clinical trial specifically studying the combination of tirzepatide plus levocarnitine versus tirzepatide alone

13 The SURMOUNT-2 study follows the same methodology as SURMOUNT-1, but it compares tirzepatide 10 mg and 15 mg with placebo in patients with T2DM who have obesity or are overweight

"Tirzepatide: A Systematic Update"

10.1056/nejm199205143262003

For recurrent injection site reactions that occur with every dose, schedule a non-urgent appointment with your healthcare provider or diabetes care and education specialist (CDCES)

It belongs to a class of medications known as dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonists